← boardnext 2027-03
STOK
Stoke Therapeutics, Incdistress 3/10 · well-funded / low risk$28.46-2%today-26% from 52w high
Lead: Dravet syndrome
Revenue
pre-revenue
Liquidity
$156M
Runway
1.1 yrs
Shares 1y
+14%
Price & events
-5.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.7%
1D
-2.2%
1W
-8.5%
1M
-18.5%
3M
-3.4%
6M
+99.4%
1Y
+95.2%
2Y
-7.2%
5Y
-51.0%
All
Overview
- Market Cap
- $1.77B
- Volume
- 26.32K
- 52 Week Range
- $11.75 – $38.35
- Total Shares
- 62.28M
- Float Shares
- 46.77M
- Short %
- 23.23%
- % Held by Insiders
- 3.82%
- % Held by Institutions
- 120.21%
- RVOL
- 0.03x
- Beta
- 1.18
Pipeline stages · 1 programs
zorevunersen (STK-001)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-03 Estimated 50% readout ~2027-05-15 | Phase 3 | zorevunersenorphanbreakthroughrare pediatric | Dravet Syndrome | — | recruiting |
| 2029-03-31 Estimated 50% readout ~2029-05-15 | Phase 2 | zorevunersen (STK-001)orphanbreakthroughrare pediatric | Dravet Syndrome | — | active not recruiting |
Catalyst news & presentations · 15
- second half of 2027Guided 55%readoutPhase 3zorevunersen · Pivotal data readout from EMPEROR study expectedSEC 8-K
- third quarter of 2027Guided 70%readoutPhase 3zorevunersen · Phase 3 data readout from primary analysis population to complete rolling NDA submissionSEC 8-K
- mid-2027Guided 55%readoutPhase 3zorevunersen · Phase 3 data readout from EMPEROR studySEC 8-K
- first half 2027Guided 55%regulatory submissionFiled (NDA/BLA)zorevunersen · Initiate rolling NDA submission to FDASEC 8-K
- first quarter of 2027Guided 70%regulatory submissionFiled (NDA/BLA)zorevunersen · Initiate rolling NDA submission to FDASEC 8-K
- August 2026Estimated 45%enrollment completesecondaryPhase 3zorevunersen · Expected last patient enrollment in European cohort of EMPEROR studySEC 8-K
- 2026-08-11earningsEarningsEarnings releaseyahoo
- Q2 2026enrollment completesecondaryPhase 3zorevunersen · Complete enrollment of 150 patients in EMPEROR studySEC 8-K
- January 13, 2026conferencedata presentationsecondaryCorporate presentation at J.P. Morgan Healthcare ConferenceSEC 8-K
- todaytrial initiationsecondaryPhase 1STK-002 · Phase 1 OSPREY study initiated.SEC 8-K
- August 11, 2025trial initiationsecondaryPhase 3zorevunersen · First patient dosed in global Phase 3 EMPEROR study.SEC 8-K
- July 10, 2025, 11:51 AM CESTconferencedata presentationsecondaryPhase 3zorevunersen · Data from analysis informing Phase 3 EMPEROR study design presented at EPNS Congress.SEC 8-K
- second quarter of 2025trial initiationsecondaryPhase 3zorevunersen · Initiate Phase 3 EMPEROR studySEC 8-K
- 2025-02-14partnershipzorevunersen · License and Collaboration Agreement with Biogen for development and commercialization outside US/Canada/MexicoSEC 8-K
- 2025-01-07fda agreementzorevunersen · Regulatory alignment with FDA, EMA, PMDA on Phase 3 study designSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $46 (+61% upside) · 11 analysts
- 2026-07-13Goldman SachsBuy
- 2026-05-11BTIGBuy
- 2026-03-20Canaccord GenuityBuy
- 2026-03-19BTIGBuy
- 2026-03-18WedbushOutperform
- 2026-03-18Chardan CapitalBuy
Competitors — Dravet syndrome
Recent news
- 2026-07-23(STOK) and the Role of Price-Sensitive Allocations - Stock Traders Daily
- 2026-07-19Stoke Therapeutics: Its Dravet Syndrome Lead Asset Enters The Last Stretch (NASDAQ:STOK) - Seeking Alpha
- 2026-07-17Form 4 Stoke Therapeutics Inc For: 17 July By Investing.com - Investing.com Nigeria
- 2026-07-17Stoke Therapeutics Chief Scientific Officer Thomas McCauley files initial beneficial ownership statement - Bitget
- 2026-07-17Stoke Therapeutics (STOK) awards 225,000 stock options to Chief Scientific Officer - Stock Titan
- 2026-07-17Stoke Therapeutics (STOK) CSO Thomas McCauley files initial insider report - Stock Titan
- 2026-07-17Stoke Therapeutics Chief Scientific Officer Thomas McCauley files initial beneficial ownership statement - Bitget
- 2026-07-17Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - July 16, 2026 - BioSpace
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.